Viking's shares received a boost from a pair of catalysts last month.
News & Analysis: Viking Therapeutics
Are intrepid short-sellers taking advantage of misguided enthusiasm?
Bargain hunting? These out-of-favor biotech and e-commerce stocks should appeal to value investors.
Investors were impressed with updated results for the company's lead candidate.
VKTX earnings call for the period ending December 31, 2018.
Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.
Once-sky-high stocks of pharmaceutical companies pursuing treatments for NASH have gotten a lot cheaper, especially this one.
Here's why Viking Therapeutics, Cambrex, and Sarepta Therapeutics are all solid biotech plays this month.
A rival's setback is this small cap's gain, right?
It's not the low share price that makes these stocks attractive, it's their huge growth prospects.